- COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME
-
Disclosed herein are embodiments of a method for treating or preventing cytokine release syndrome (CRS). In certain embodiments, the method comprises administering a compound, or a salt, solvate, prodrug or pharmaceutical composition thereof, to a subject experiencing, or at risk of developing, CRS. The compound may be a kinase inhibitor, such as a JAK inhibitor and/or an IRAK inhibitor, and/or the compound may have a structure according to Formulas I, III, IV or VII. And the method may comprise administering the compound to a subject who is has received, is currently receiving, and/or will be receiving a cell therapy.
- -
-
-
- TGF-beta receptor inhibitor
-
The invention provides a compound shown as a formula (I) and a pharmaceutical composition thereof. The compound shown as the formula (I) of the present invention is useful as a TGF-beta receptor inhibitor, particularly a TGF beta RI inhibitor, for example, in the prevention or treatment of various TGF beta RI (ALK5) mediated related diseases.
- -
-
Paragraph 0142-0143; 0145; 0147-0149
(2021/04/28)
-
- Preparation method of 2-methyl-5-aminobenzenesulfonamide
-
The invention relates to a preparation method of 2-methyl-5-aminobenzenesulfonamide. The preparation method includes following steps: S1, allowing sulfonation: dissovling p-nitrotoluene and chlorosulfonic acid in an organic solvent I, stirring for reaction, and performing aftertreatment to obtain 2-methyl-5-nitrobenzene sulfonyl chloride; S2, allowing hydrogenation and addition: adding 2-methyl-5-nitrobenzene sulfonyl chloride obtained in the S1 into a hydrogenation kettle, sequentially adding a catalyst, ammonia water and an organic solvent II, allowing reaction at high temperature and high pressure, treating after reaction to obtain 2-methyl-5-aminobenzenesulfonamide which is light yellow solid. The preparation method has the advantages of short route, high product purify and easiness for industrial production.
- -
-
Paragraph 0052; 0066; 0070
(2018/04/15)
-
- N,N'-bis-substituted aryl thiourea derivatives and synthetic method and application thereof
-
The invention discloses N,N'-bis-substituted aryl thiourea derivatives which are a series of compounds simultaneously containing various substituted aromatic ring structures and asymmetric substituted thiourea structures and are all novel structural compounds which are not reported in the literature. The biological activity test analysis of all the target compounds includes determination of DPPH antioxidant activity and antiviral activity. Results indicate that, in general, the designed and synthesized compounds are novel in structures and have the antioxidant activity and the antiviral activity revealed for the first time. In addition, the unknown biological activity is not fully elucidated, and thus the compounds are expected to provide a certain material basis for further research and development of new drugs.
- -
-
Paragraph 0069; 0074; 0075
(2017/04/26)
-
- TREATMENT FOR VITILIGO
-
Compounds I and II, as well as prodrugs, hydrates, solvates, N-oxides, salts and pharmaceutical compositions containing them, are useful for treating vitiligo. In certain embodiments, the compounds are provided in topical compositions.
- -
-
-
- COMPOSITION FOR OPHTHALMIC ADMINISTRATION
-
Disclosed herein are embodiments of a composition useful for treating and/or preventing dry eye disorders. The disclosed composition comprises components that maintain the composition's chemical and/or physical properties thereby providing a composition suitable for use.
- -
-
-
- TREATMENT FOR DISCOID LUPUS
-
Compounds I and II as well as salts and pharmaceutical compositions containing them are useful for treating diseases and/or disorders of the skin, such as cutaneous lupus, for example acute cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, or discoid lupus erythematosus. In certain embodiments, the compounds are provided in topical compositions.
- -
-
-
- COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
-
Compounds I and II as well as salts and pharmaceutical compositions containing them are useful for treating diseases and/or disorders of the eye.
- -
-
Page/Page column 11
(2011/02/25)
-
- Treatment Method
-
The present invention is directed to methods of treating an ocular neovascular disorder in a mammal by administration of pyrimidine derivatives, benzodiazepinyl derivatives and pharmaceutical compositions containing the same. The invention encompasses methods of treating an ocular neovascular disorder by administration of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, (S)-3-oxo-8-[3-(pyridin-2-ylamino)-1-propyloxy]-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid or salts or solvates thereof. Combination therapies for the treatment of ocular neovascular disorders are also encompassed.
- -
-
Page/Page column 10
(2009/01/20)
-
- COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
-
The invention encompasses compounds having formula (I-V) and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.
- -
-
Page/Page column 193
(2008/06/13)
-
- CANCER TREATMENT METHOD
-
A method of treating cancer is described including administration of a pyrimidine derivative and a quinazoline derivative as well as a pharmaceutical composition including the same.
- -
-
Page/Page column 33-34
(2010/02/14)
-
- CHEMICAL PROCESS
-
A process for the preparation of pyrimidine derivatives, which are useful as VEGFR2 inhibitors is described herein. The described invention also includes pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.
- -
-
-